Sai Life Sciences, one of India’s leading integrated CDMOs (Contract Development and Manufacturing Organizations), has announced a major expansion of its Hyderabad campus with the construction of a new 100,000 sq. ft. CMC Process R&D facility. 

Scheduled for completion by September 2026, the project will double the company’s R&D capacity and include specialized labs for peptides, oligonucleotide intermediates, and formulation sciences. 

Sai Life Sciences has been a crucial partner for several global pharma innovators, supporting drug discovery to commercial-scale manufacturing. 

The new facility aligns with the company’s sustainability goals, featuring green building design and waste-minimization systems. 

As India continues to grow as a global pharmaceutical powerhouse, Sai’s expansion strengthens its position in the international drug development supply chain.